Sign in
CompletedPhase 4

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

Key facts

Who runs it
Henry M. Jackson Foundation for the Advancement of Military Medicine
Where
Annapolis, Bethesda, Fort Bragg, Fort Sam Houston, Portsmouth, San Antonio, San Diego, and Tacoma, United StatesSee the 9 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
15,448 people enrolled
Started
6 Nov 2018
Ended
30 Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Egg based influenza vaccines
  • Recombinant influenza vaccines
  • Cell-culture based influenza vaccines
Record updated
10 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Eligible for care in Department of Defense medical facilities (Defense Enrollment Eligibility Reporting System eligible)
  • ≥18 years of age
  • At a participating Military Treatment Facility site for the purpose of receiving a seasonal (2018-2019, 2019-2020,2020-2021, 2021-2022) influenza vaccination
  • Able to speak English and able to provide informed consent
  • Able to receive and respond to texts and/or emails, or a military recruit

Who cannot take part

  • Adults intending to receive or who have received the current seasons FluMist Vaccine (LAIV)
  • Adults who have already received a flu vaccine within the current season
  • Individual who cannot receive a flu vaccine or standard dosing due to another medical condition
  • Allergic to gentamicin, polymyxin and/or neomycin
  • Individuals who fail to meet the inclusion criteria

Where in United States

  • United States Naval AcademyAnnapolis, United States
  • USUBethesda, United States
  • Walter Reed National Military Medical CenterBethesda, United States
  • Womack Army Medical CenterFort Bragg, United States
  • Brooke Army Medical CenterFort Sam Houston, United States
  • Naval Medical Center - PortsmouthPortsmouth, United States
  • Lackland Airforce BaseSan Antonio, United States
  • Naval Medical Center -San DiegoSan Diego, United States
  • Madigan Army Medical CenterTacoma, United States

About the trial

What the trial wants to find out

A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).

The 3 groups in the trial

  • Egg based influenza vaccinesExisting treatment, for comparison

    Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.

  • Recombinant influenza vaccinesExisting treatment, for comparison

    FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.

  • Cell-culture based influenza vaccinesExisting treatment, for comparison

    Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
10 November 2026